✦ LIBER ✦

Targeted therapy with bevacizumab and erlotinib tailored to the molecular profile of patients with recurrent glioblastoma. Preliminary experience

✍ Scribed by Quintino Giorgio D’Alessandris, Nicola Montano, Tonia Cenci, Maurizio Martini, Liverana Lauretti, Federico Bianchi, Luigi Maria Larocca, Giulio Maira, Eduardo Fernandez, Roberto Pallini

Book ID: 118788800
Publisher: Springer Vienna
Year: 2012
Tongue: English
Weight: 397 KB
Volume: 155
Category: Article
ISSN: 0001-6268
DOI: 10.1007/s00701-012-1536-5

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

977 Phase I/II trial evaluating blockade

977 Phase I/II trial evaluating blockade of tumour blood supply and tumour cell proliferation with combined bevacizumab and erlotinib HCl as targeted cancer therapy in patients with recurrent non-small cell lung cancer

✍ R.S. Herbst; E. Mininberg; T. Henderson; E. Kim; W.K. Hong; R. Mass; W. Novotny; 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 174 KB

Autologous Glioma Cell Vaccine Admixed w

Autologous Glioma Cell Vaccine Admixed with Interleukin-4 Gene Transfected Fibroblasts in the Treatment of Recurrent Glioblastoma: Preliminary Observations in a Patient with a Favorable Response to Therapy

✍ Hideho Okada; Frank S. Lieberman; Howard D. Edington; Timothy F. Witham; Mark J. 📂 Article 📅 2003 🏛 Springer US 🌐 English ⚖ 209 KB

The use of molecular assays to establish

The use of molecular assays to establish definitively the clonality of ipsilateral breast tumor recurrences and patterns of in-breast failure in patients with early-stage breast cancer treated with breast-conserving therapy

✍ Frank A. Vicini; J. Vito Antonucci; Neal Goldstein; Michelle Wallace; Larry Kest 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 100 KB 👁 1 views

## Abstract ## BACKGROUND. Results from numerous trials have indicated that breast‐conserving therapy (BCT) produces outcomes equivalent to those produced by mastectomy in terms of both locoregional control and survival. However, conservative treatment has resulted in the dilemma of how best to ad

Molecular Gene Expression Profiling to P

Molecular Gene Expression Profiling to Predict the Tissue of Origin and Direct Site-Specific Therapy in Patients With Carcinoma of Unknown Primary Site: A Prospective Trial of the Sarah Cannon Research Institute

✍ Hainsworth, J. D.; Rubin, M. S.; Spigel, D. R.; Boccia, R. V.; Raby, S.; Quinn, 📂 Article 📅 2013 🏛 American Society of Clinical Oncology 🌐 English ⚖ 154 KB